Multiple Sclerosis (MS) and Alzheimers Disease (AD) MS and Alzheimer's Disease
Conditions
Interventions
n.v.t.
Sponsors
Amsterdam UMC
Eligibility
Age
18 Years to 99 Years
Inclusion criteria
Inclusion criteria: General inclusioncriteria (Everyone):The participant must be willing and mentally competent of providing written informed consent prior to study entry. The participant must be 18 years or older. Specific inlcusioncriteria per participant group:Healthy controls:The participant has no known cognitive abnormalities (no memory complaints that the participant worries about).People with Alzheimer’s Disease:The participant has a confirmed biological diagnosis of (early-stage) Alzheimer’s disease.This diagnosis is established through CSF Abeta42 analysis or amyloid PET imaging.The participant does not yet show extensive clinical symptoms of the disease.People with Multiple Sclerosis (MS):The participant has a clinical diagnosis of MS based on consultation with a neurologist.
Exclusion criteria
Exclusion criteria: The participant is 17 years old or younger. The participant has a significant diagnosed bleeding disorderThe participant is currently taking anticoagulant or antiplatelet medication that could interfere with blood collection or increase risk of complications. The participant has a contra-indication for venipuncture The participant is uncomfortable with (self-)sampling of blood.
Design outcomes
Primary
| Measure | Time frame |
|---|---|
| In this study the feasibility of testing for neurodegenerative biomarkers using multiple capillary self-sampling devices is determined. The primary parameters are: Correlation between different blood samples taken with capillary self-sampling devices and venous blood sample is examined using statistics. Intra-individual variability of the biomarkers over 5 days is determined. This helps determine stability of biomarkers in capillary samples and sampling methods. | — |
Secondary
| Measure | Time frame |
|---|---|
| The effect of pre-analytics on the biomarker levels is examined. The quality of each self-acquired sample is inspected and analytically determined, similar to a previous study. After completion of multiple self-samplings using various devices, the participant satisfaction is measured for each used device with a questionnaire. The overall receivability of the device is determined based on these results and incorporated in the device evaluation together with the success rate of sampling per device. | — |
Countries
Netherlands
Contacts
Public ContactF.I. van der Zee
Amsterdam UMC
Outcome results
None listed